INDOCO2024-10-012024-12-31 INDOCO2024-10-012024-12-31 INDOCO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member INDOCO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member INDOCO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member INDOCO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member INDOCO2024-12-31 INDOCO2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDOCO2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2024-04-01 2025-03-31 2025-01-21 2025-01-13 INR Lakhs Third quarter 11:10:00 12:20:00 2025-01-21 2025-01-21 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 4105500000.00 8500000.00 4114000000.00 1099100000.00 349300000.00 -309200000.00 975500000.00 161100000.00 287200000.00 1870500000.00 4433500000.00 -319500000.00 9900000.00 -309600000.00 -50000000.00 24400000.00 -25600000.00 0.00 -284000000.00 0.00 0.00 0.00 0.00 -284000000.00 -1300000.00 -285300000.00 -263900000.00 -20100000.00 -265200000.00 -20100000.00 184400000.00 2 -3.08 -3.08 0.00 0.00 -3.08 -3.08 1.The unaudited Consolidated Results for the quarter and Nine months ended 31st December, 2024 have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 21st January, 2025. The Statutory Auditors have expressed an Unmodified Audit Opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Qtr ended Qtr ended Qtr ended Nine mths Nine mths Year ended and Income 31.12.2024 30.09.2024 31.12.2023 ended ended 31.03.2024 from (Unaudited) (Unaudited) (Unaudited) 31.12.2024 31.12.2023 (Audited) Operations (Unaudited) (Unaudited) --------------------------------------------------------------------------------------------------------------------------------------- India 28,162 29,016 24,833 82,853 74,307 96,758 Outside India 12,083 14,050 21,042 42,887 60,607 82,064 ----------------------------------------------------------------------------------------------------------------------------- Total : 40,245 43,066 45,875 1,25,740 1,34,914 1,78,822 5. The Consolidated Financial Results includes the Results of the following Companies ---------------------------------------------------------------------------------------------------------------------------------- Name of theCompany % of shareholding Consolidated as --------------------------------------------------------------------------------------------------------------------------------- Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary Indoco Remedies Czech SRO 100.00 Subsidiary Indoco Remedies UK Ltd 100.00 Subsidiary Warren Remedies Private Limited 100.00 Subsidiary FPP Holding Company , LLC 85.00 Subsidiary ================================================================= 6.The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December, 2024. 7. (*) Exceptional items include consideration received Rs. 99.4 lacs for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 12747100000.00 34300000.00 12781400000.00 3104100000.00 1103100000.00 -285100000.00 2876900000.00 482500000.00 850600000.00 4947700000.00 13079800000.00 -298400000.00 9900000.00 -288500000.00 31700000.00 45900000.00 77600000.00 0.00 -366100000.00 0.00 0.00 0.00 0.00 -366100000.00 -12000000.00 -378100000.00 -333500000.00 -32600000.00 -345500000.00 -32600000.00 184400000.00 2 3.97 3.97 0.00 0.00 3.97 3.97 OTHER EXPENSES 1683900000.00 RESEARCH & DEVELOPMENT EXPENSES 186600000.00 OTHER EXPENSES 4361500000.00 RESEARCH & DEVELOPMENT EXPENSES 586200000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS -3000000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS -9000000.00 -3000000.00 -9000000.00 -700000.00 -2300000.00 ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS 1200000.00 ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS -7000000.00 1200000.00 -7000000.00 200000.00 -1700000.00